Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma

BACKGROUND: Surgery is the primary treatment for basal cell carcinoma (BCC). In locally advanced basal cell carcinoma (laBCC), surgery may cause functional or aesthetic damage. In laBCC, neoadjuvant administration of vismodegib, an inhibitor of the Hedgehog signaling pathway, may reduce tumor size,...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:EClinicalMedicine
Päätekijät: Bertrand, Nicolas, Guerreschi, Pierre, Basset-Seguin, Nicole, Saiag, Philippe, Dupuy, Alain, Dalac-Rat, Sophie, Dziwniel, Véronique, Depoortère, César, Duhamel, Alain, Mortier, Laurent
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Elsevier 2021
Aiheet:
Research paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8093898/
https://ncbi.nlm.nih.gov/pubmed/33997740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eclinm.2021.100844
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia